Long

EQS-News: Screening completed: Berlin Cures achieves key milestone in BC 007 Phase II Trial for treatment of Long COVID

Retrieved on: 
금요일, 5월 3, 2024
Long, Patient, ME/CFS, Glaucoma, Heart failure, Pharmaceutical industry

Berlin, Germany, 23 April 2024 – Berlin Cures, a pioneering clinical-stage biotechnology company, today announced the successful completion of patient screening for its pan-European Phase II trial of BC 007 (Rovunaptabin), a novel therapeutic candidate for the treatment of Long COVID.

Key Points: 
  • Berlin, Germany, 23 April 2024 – Berlin Cures, a pioneering clinical-stage biotechnology company, today announced the successful completion of patient screening for its pan-European Phase II trial of BC 007 (Rovunaptabin), a novel therapeutic candidate for the treatment of Long COVID.
  • The drug candidate BC 007 targets these harmful fAABs, which are believed to play a critical role in the symptoms associated with Long COVID.
  • With the trial fully recruited, Berlin Cures is actively preparing for the subsequent Phase III study, which will be essential for gaining regulatory approval and bringing BC 007 to market.
  • The company is currently actively seeking funding partners to initiate Phase III as soon as possible following the successful completion of Phase II.

Tonix Pharmaceuticals Announces Presentation at Planet MicroCap Showcase

Retrieved on: 
수요일, 4월 24, 2024
FDA, CD40L, Cancer, Sumatriptan, NDA, Long, Food, Risk, Planet, Disease, Annual report, Security (finance), Cocaine, Research, CNS, Therapy, Failure, Infection, Central nervous system, Government, Breakthrough therapy, Fibromyalgia, Autoimmunity, Pharmaceutical industry

The presentation will include data from the recently reported positive Phase 3 RESILIENT trial of Tonmya™ (also known as TNX-102 SL) for the management of fibromyalgia.

Key Points: 
  • The presentation will include data from the recently reported positive Phase 3 RESILIENT trial of Tonmya™ (also known as TNX-102 SL) for the management of fibromyalgia.
  • A copy of the Company’s presentation will be available under the Presentations tab of the Tonix website at www.tonixpharma.com following the conference.
  • Additional meeting information can be found on the showcase website .
  • Tonix is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering.

The Rosen Law Firm, P.A. Announces Proposed Class Action Settlement on Behalf of Purchasers of the publicly-traded common stock of Hanmi Financial Corporation – HAFC

Retrieved on: 
월요일, 4월 15, 2024
Class Action, Hearing, Claim, Prejudice, Long, TEL, Postcard, HAFC, COMMON, BOTH, District court, Court, Lead, Fault, Judgement, Settlement, ALL, Fax

announces that the United States District Court for the Central District of California has approved the following announcement of a proposed class action settlement that would benefit purchasers Hanmi Financial Corporation publicly-traded common stock (NASDAQ: HAFC):

Key Points: 
  • announces that the United States District Court for the Central District of California has approved the following announcement of a proposed class action settlement that would benefit purchasers Hanmi Financial Corporation publicly-traded common stock (NASDAQ: HAFC):
    TO: ALL PERSONS AND ENTITIES WHO PURCHASED THE PUBLICLY-TRADED COMMON STOCK OF HANMI FINANCIAL CORPORATION (“HANMI”) FROM AUGUST 9, 2018 THROUGH APRIL 30, 2020, BOTH DATES INCLUSIVE.
  • Box 230, Media, PA 19063; (Tel) (866) 274-4004; (Fax) (610) 565-7985; [email protected] , or going to the website, www.strategicclaims.net/Hanmi .
  • Unless you submit a written exclusion request, you will be bound by any judgment rendered in the Action whether or not you make a claim.
  • All members of the Settlement Class who have not requested exclusion from the Settlement Class will be bound by any judgment entered in the Action.

Virax Biolabs Launches Portfolio of Immune Profiling Solutions Evaluating Adaptive Immunity in Post-Viral Syndromes at ESCMID Global 2024

Retrieved on: 
목요일, 4월 25, 2024
Infection, Congress, Recombinant antibodies, SARS-CoV-2, Long, Viral, ELISA, ESCMID, Cytokine, Epitope, Lyme disease, Research, ELISpot, Immunology, Diagnosis, Long COVID, Biomarker, Immunity, Flow cytometry, CD8, Vaccine

The Company is hosting at Booth F43, and management will be available for discussions with research organizations and potential partners.

Key Points: 
  • The Company is hosting at Booth F43, and management will be available for discussions with research organizations and potential partners.
  • "We are very pleased to launch ImmuneSelect, an important portfolio of immune profiling solutions within our ViraxImmune™ T-Cell diagnostic platform," commented Mr. James Foster, Chief Executive Officer of Virax Biolabs.
  • "The launch marks a significant milestone for Virax as it brings us a step closer to commercializing ViraxImmune™ as a full In-Vitro-Diagnostic product."
  • ImmuneSelect is the Company's new portfolio of immune profiling solutions dedicated to investigating adaptive immunity.

EQS-News: Berlin Cures Expands Research Capabilities and Scientific Expertise with New Advisory Board

Retrieved on: 
수요일, 4월 10, 2024
Research, Glaucoma, COVID, ME/CFS, Diabetes, Patient, Biomarker, OBE, University, Long, Heart failure, Chronic kidney disease, Maastricht University, Cardiomyopathy, Pharmaceutical industry

Berlin, Germany, 3 April 2024 – Berlin Cures, a biotechnology company in Phase II clinical trial for a treatment against Long COVID, appoints six distinguished scientists to a new advisory board.

Key Points: 
  • Berlin, Germany, 3 April 2024 – Berlin Cures, a biotechnology company in Phase II clinical trial for a treatment against Long COVID, appoints six distinguished scientists to a new advisory board.
  • The aim of the board is to advise on industry developments and new growth potentials, as well as to support research and development that will further strengthen the portfolio of Berlin Cures and thus the successful market launch of new therapies.
  • “We are very pleased to now work with six renowned scientists who have achieved great success in their respective fields of research.
  • Berlin Cures has been known for innovative and effective research for years.

Tonix Pharmaceuticals Announces Pricing of $4.4 Million Registered Direct Offering

Retrieved on: 
목요일, 3월 28, 2024
Failure, Madison Avenue, Exercise, Fibromyalgia, Infection, Cocaine, Autoimmunity, Central nervous system, Form, Telephone, Patient, CNS, Research, Sale, NDA, Disease, Cancer, Long, Security (finance), Breakthrough therapy, Nature, Risk, Annual report, Therapy, Series, CD40L, FDA, Sumatriptan, Government, Food

The closing of the offering is expected to take place on or about April 1, 2024, subject to the satisfaction of customary closing conditions.

Key Points: 
  • The closing of the offering is expected to take place on or about April 1, 2024, subject to the satisfaction of customary closing conditions.
  • The gross proceeds of the offering will be approximately $4.4 million before deducting placement agent fees and other estimated offering expenses payable by the Company.
  • A.G.P./Alliance Global Partners is acting as sole placement agent for the offering.
  • This offering is being made pursuant to an effective shelf registration statement on Form S-3 (File No.

Winners Announced for the 2024 JUNO Opening Night Awards Presented by Music Canada

Retrieved on: 
일요일, 3월 24, 2024
Instrumental, Juno Award, CARAS, GO, Single, Long, JUNO, Walt Grealis, Radio, Songwriter, Artist, SOCAN, Music Canada, Sirius XM Canada, WINNERS, NS, Halifax Convention Centre, Music

Special honours presented to Chip Sutherland (Walt Grealis Special Achievement Award) and performances from Aqyila, Begonia, Jah'Mila, Lili-Ann De Francesco and LU KALA.

Key Points: 
  • Special honours presented to Chip Sutherland (Walt Grealis Special Achievement Award) and performances from Aqyila, Begonia, Jah'Mila, Lili-Ann De Francesco and LU KALA.
  • HALIFAX, NS, March 23, 2024 /CNW/ - The Canadian Academy of Recording Arts and Sciences (CARAS) celebrated the artists and industry veterans at the top of Canada's music scene this evening at the 2024 JUNO Opening Night Awards Presented by Music Canada, at the Halifax Convention Centre.
  • The industry event was co-hosted by Aba Amuquandoh and Damhnait Doyle, featuring the presentation of 40+ JUNO Awards including Chip Sutherland receiving the Walt Grealis Special Achievement Award.
  • FOR A COMPLETE LIST OF WINNERS AT THE 2024 JUNO OPENING NIGHT AWARDS, GO TO WWW.JUNOAWARDS.CA .

Global Times: More artworks displaying beauty of Chinese civilization, spirit of the times need to be 'invited abroad': artist Wu Weishan

Retrieved on: 
월요일, 3월 11, 2024
Tao, Shitao, Conference, Education, Individual, Real-time, CPPCC, Prejudice, Tourism, Long March, Nanjing University, Rejuvenation, Museum, Philosophy, Beauty, Confucius, Painting, School, Writing, Artificial intelligence, Policy, Interview, Laetare Sunday, AI, Long, River, Student, Sculpture, Global Times, CPC, Peasant, Civilization, Terracotta Army, Dance, Exhibition, Vocabulary, Creativity, Curriculum, Nursing, Literature, Western world, Great hall, Ministry, Lunch, National Museum of Art, Politics, Singing, Army, National Committee, Entertainment

How does he portray the spirit and beauty of Chinese civilization through the array of well-known sculptures, paintings and calligraphy works he has created?

Key Points: 
  • How does he portray the spirit and beauty of Chinese civilization through the array of well-known sculptures, paintings and calligraphy works he has created?
  • According to Wu, both historical and contemporary arts are important windows for the outside world to learn about Chinese culture and stories.
  • Wu said the sculpture carries great global ramifications in terms of the progress of human civilization and the global exchanges of philosophy.
  • Since the 1990s, Wu has created about 600 sculptures of prominent figures in Chinese history, which Wu said all embody the excellent qualities and spirit of Chinese civilization.

Tonix Pharmaceuticals Announces Presentation at The 6th International Congress on Controversies in Fibromyalgia

Retrieved on: 
목요일, 2월 29, 2024
Therapy, Central nervous system, Cocaine, Annual report, CD40L, FDA, Food, Sumatriptan, Government, Disease, Autoimmunity, Science, CNS, Security (finance), Infection, Long, Breakthrough therapy, Risk, NDA, Failure, Research, Cancer, Pharmaceutical industry

The presentation will include additional data from the recently reported positive Phase 3 RESILIENT trial of Tonmya™ (also known as TNX-102 SL) for the management of fibromyalgia.

Key Points: 
  • The presentation will include additional data from the recently reported positive Phase 3 RESILIENT trial of Tonmya™ (also known as TNX-102 SL) for the management of fibromyalgia.
  • A copy of the Company’s presentation will be available under the Scientific Presentations tab of the Tonix website at www.tonixpharma.com following the conference.
  • Tonix is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering.
  • All of Tonix's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements.

NeuroMetrix Reports Q4 and Full Year 2023 Business Highlights

Retrieved on: 
목요일, 2월 22, 2024
CIPN, PIN, CMS, Pressure, Absorption, Telephone, FDA, Telehealth, Growth, Peripheral neuropathy, Common, Risk, COVID-19, Medicare, Fibromyalgia, DSM-IV codes, CDC, Long, Prescription, Environment, Baylor University, Pharmaceutical industry

WOBURN, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter and full year ended December 31, 2023.

Key Points: 
  • WOBURN, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter and full year ended December 31, 2023.
  • "Quell® Fibromyalgia growth accelerated in Q4 2023 reflecting the addition in Q3 2023 of two field business development managers and optimized clinical messaging.
  • In the successive quarters of Q4 2023 versus Q3 2023, all key operating metrics showed substantial growth.
  • The Q4 2023 net loss was $1.6 million ($1.43 per share) versus a net loss of $0.7 million ($0.73 per share) in Q4 2022.